Unknown PHASE1 INTERVENTIONAL 1-arm NCT03751293

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma

Sponsor: Hebei Yanda Ludaopei Hospital

Conditions Relapsed or Refractory Multiple Myeloma

Interventions C-CAR088

Updated 6 times since 2018 Last updated: May 13, 2019 Started: Jan 8, 2019 Primary completion: Oct 30, 2019 Completion: Oct 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Relapsed or Refractory Multiple Myeloma and is currently ongoing. Hebei Yanda Ludaopei Hospital leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1
Jun 2019 — Jan 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Dec 2018 — Jun 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebei Yanda Ludaopei Hospital

Data source: Hebei Yanda Ludaopei Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sanhe, China